{"product_id":"rvmd-ansoff-analysis","title":"(RVMD) Revolution Medicines, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Revolution Medicines, Inc. Ansoff Matrix Analysis distills the company’s growth options across market penetration, market development, product development, and diversification into a concise, actionable framework; it’s designed for strategy, investing, or planning. The page shows a real preview\/sample of the analysis so you can judge style and substance—purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-4630 Phase 1\/2 solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-4630 is already in Phase 1\/2 testing in solid tumors, so Revolution Medicines is deepening its reach in the same RAS-driven oncology lane instead of opening a new one. The gynecological and colorectal cohorts add direct evidence in two high-burden areas, where colorectal cancer alone caused about 53,000 U.S. deaths in 2024. That kind of cohort breadth can improve later trial design and strengthen market fit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-6236 RAS(ON) solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-6236 targets active RAS(ON) variants, and KRAS mutations sit behind about 25% of cancers, so the program fits Revolution Medicines, Inc.’s core precision-oncology niche. Moving it deeper in RAS-driven tumors can widen use across the same market, especially in solid tumors like NSCLC, where KRAS mutations are found in about 25% to 30% of cases. That supports market penetration inside the company’s current therapeutic focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-6291 KRASG12C(ON) and NRASG12C(ON)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-6291 keeps Revolution Medicines, Inc. focused on the same biomarker-defined RAS cancer pool, but with tighter selectivity for KRASG12C(ON) and NRASG12C(ON). That supports market penetration by widening share inside an already served niche, not by chasing a new market. The program builds on the same precision-oncology base and can deepen use in the 5% to 15% KRASG12C-mutant solid-tumor subgroup.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eColorectal and gynecological cohorts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevolution Medicines, Inc. is using colorectal and gynecological cohorts in RMC-4630 to defend and expand its share in established solid tumors. Colorectal cancer remains one of the largest RAS-linked markets, with about 1.9 million new cases worldwide in 2022, and gynecologic tumors add another repeat setting where RAS biology can matter. That gives the company more shots on goal in known oncology segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eColorectal is a large RAS market.\u003c\/li\u003e\n\u003cli\u003eGynecologic cohorts widen reuse.\u003c\/li\u003e\n\u003cli\u003eRMC-4630 gains repeated exposure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSanofi SHP2 collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevolution Medicines’ Sanofi SHP2 deal strengthens market penetration in its existing SHP2 inhibitor field by pairing RMC-4630 with Sanofi’s external development muscle. That keeps the program centered on the same target while widening validation and execution support. The collaboration matters because SHP2 is a key upstream node in RAS signaling, a core area for Revolution Medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports the same SHP2 asset base\u003c\/li\u003e\n\u003cli\u003eAdds external R\u0026amp;D capacity\u003c\/li\u003e\n\u003cli\u003eReinforces existing market position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevolution Medicines Deepens Its RAS Oncology Niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevolution Medicines, Inc. is using RMC-4630, RMC-6236, and RMC-6291 to deepen share in its core RAS-driven oncology niche, not enter new markets. KRAS mutations drive about 25% of cancers, and KRAS appears in 25% to 30% of NSCLC cases, so the same target pool stays large. RMC-6291 also taps the 5% to 15% KRASG12C subgroup.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket Penetration Signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-6236\u003c\/td\u003e\n\u003ctd\u003eRAS(ON) solid tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-6291\u003c\/td\u003e\n\u003ctd\u003eKRASG12C\/NRASG12C niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Revolution Medicines, Inc.’s business growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, structured Ansoff view for Revolution Medicines, Inc. to simplify growth planning across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary company filings, clinical trial registries, investor presentations, peer-reviewed studies, and reputable industry reports to validate Ansoff Matrix growth paths for Revolution Medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-4630 gynecological cancer entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-4630’s study in gynecological cancers is a clear market development move: the same SHP2 program is being tested in a new patient pool without changing the drug. Gynecologic cancers still create large unmet need, with ovarian cancer alone causing about 313,000 new cases and 207,000 deaths worldwide each year. If the signal holds in 2025-2026 studies, Revolution Medicines, Inc. can widen use beyond its core tumor set.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-4630 colorectal cancer entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-4630’s colorectal cancer program moves Revolution Medicines, Inc. into a larger solid-tumor pool, as colorectal cancer ranks among the world’s most common cancers, with about 1.9 million new cases and 900,000 deaths a year. The molecule stays the same; only the target segment changes, which fits market development in the Ansoff Matrix. It can add upside without needing a new product platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-6236 broader RAS-driven cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-6236 targets active RAS(ON) variants, so Revolution Medicines can move from a tight biomarker niche into a wider RAS-driven cancer pool. Early clinical data have shown activity across at least 3 tumor types, including pancreatic, lung, and colorectal cancers, which supports a bigger total addressable market. That same molecule can be reused across more cohorts without rebuilding the drug from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRMC-6291 mutant tumor expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRMC-6291 can move from a single KRASG12C(ON) niche into broader mutation-defined oncology segments, including NRASG12C(ON). KRASG12C occurs in about 13% of non-small cell lung cancer and 3% to 4% of colorectal cancer, so each added tumor type expands the same asset’s reach. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne program, more subpopulations.\u003c\/li\u003e\n\u003cli\u003eKRASG12C and NRASG12C are distinct markets.\u003c\/li\u003e\n\u003cli\u003eExpansion can raise trial and sales leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKRASG13C and KRASG12D programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevolution Medicines is extending its RAS platform into KRASG13C(ON) and KRASG12D(ON), which can add new biomarker-defined solid-tumor markets beyond its lead programs. KRAS mutations drive about 25% of cancers, and KRASG12D is the most common KRAS subtype in pancreatic cancer, so the addressable pool is meaningful. This is a market-development move: the company is using the same RAS know-how to reach new patient groups.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew mutation targets: KRASG13C(ON), KRASG12D(ON)\u003c\/li\u003e\n\u003cli\u003eExpands into solid-tumor biomarker niches\u003c\/li\u003e\n\u003cli\u003eBuilds on existing RAS expertise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevolution Medicines Expands Its Cancer Reach Across New Tumor Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevolution Medicines, Inc. is using the same RAS and SHP2 assets to enter new cancer segments, which is classic market development. RMC-6236 broadens reach across pancreatic, lung, and colorectal tumors, while RMC-6291 and new KRAS targets extend the platform into more biomarker-defined pools. That raises TAM without changing the core molecule.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-6236\u003c\/td\u003e\n\u003ctd\u003eRAS(ON) solid tumors\u003c\/td\u003e\n\u003ctd\u003e3 tumor types\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-6291\u003c\/td\u003e\n\u003ctd\u003eKRASG12C\/NRASG12C\u003c\/td\u003e\n\u003ctd\u003eMore segments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-4630\u003c\/td\u003e\n\u003ctd\u003eGynecologic, colorectal\u003c\/td\u003e\n\u003ctd\u003eNew patient pools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eRevolution Medicines, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-5845 SOS1 inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-5845 is a selective SOS1 inhibitor, so it expands Revolution Medicines, Inc.’s RAS-pathway pipeline beyond its KRAS-focused assets. In Ansoff terms, this is product development: a new oncology candidate for existing cancer markets. By targeting an upstream RAS activator, it can reach tumors that still depend on SOS1-driven signaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-5552 mTORC1 inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-5552 is a highly selective mTORC1 inhibitor and a new product line for Revolution Medicines, Inc., so it fits Ansoff product development. It broadens the cancer pipeline beyond direct RAS inhibitors into the mTOR pathway, which can help diversify oncology risk. Revolution Medicines remains R\u0026amp;D-led, with no product revenue as of its latest filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMC-6291 ON-state inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-6291 is Revolution Medicines, Inc.'s ON-state inhibitor designed to block mutated KRASG12C and NRASG12C, so it fits an existing oncology market with a new therapeutic product. The drug adds a differentiated mechanism to the pipeline, which supports product development in the Ansoff Matrix. In 2025, Revolution Medicines, Inc. reported continued pipeline investment as it advanced this next-gen RAS program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRMC-6236 pan-RAS(ON) inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRMC-6236 is a product-development play: Revolution Medicines is adding a pan-RAS(ON) inhibitor to its core RAS-driven cancer franchise, aiming at the same oncology market with a broader active-variant reach. RAS mutations appear in about 19% of human cancers, so wider RAS(ON) coverage can lift pipeline depth and address more tumors without leaving the core strategy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting market, new molecule\u003c\/li\u003e\n\u003cli\u003eTargets active RAS(ON) variants\u003c\/li\u003e\n\u003cli\u003eBroadens RAS-driven cancer coverage\u003c\/li\u003e\n\u003cli\u003eFits product-development logic\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKRASG13C and KRASG12D inhibitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevolution Medicines is advancing 2 additional active RAS inhibitor programs, KRASG13C(ON) and KRASG12D(ON), to widen its mutation-focused cancer portfolio inside the same therapeutic area. This is a product development move, not a new market, and it fits Ansoff Matrix \"product development\" because the company is adding new medicines for adjacent KRAS targets. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 new mutation targets\u003c\/li\u003e\n\u003cli\u003eSame RAS oncology franchise\u003c\/li\u003e\n\u003cli\u003eExpands beyond KRASG12C\u003c\/li\u003e\n\u003cli\u003eHigher pipeline breadth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAs of 2025, Revolution Medicines still had no approved commercial oncology products, so these programs matter for future growth rather than current sales. The near-term value case depends on clinical data quality, safety, and how well these assets differentiate against other KRAS-directed drugs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevolution Medicines Deepens RAS Pipeline, but Clinical Wins Still Drive Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevolution Medicines, Inc. is using product development to add new RAS-pathway drugs for the same oncology markets. In 2025, it had no product revenue and kept funding R\u0026amp;D for RMC-6236, RMC-6291, RMC-5845, RMC-5552, and KRASG13C\/KRASG12D programs. This deepens its RAS franchise, but value still depends on clinical wins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eAnsoff fit\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-6236\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003ctd\u003eLead pan-RAS(ON) asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-6291\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003ctd\u003eKRASG12C\/NRASG12C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSHP2 plus Sanofi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSHP2 plus Sanofi adds a 2-company, partner-led development track around a distinct pathway, so Revolution Medicines, Inc. is not tied to just one internal asset lane. The SHP2 program sits in Phase 1\/2-style risk, but the Sanofi tie-up spreads scientific and execution risk across 2 firms and 1 new mechanism. That widens diversification beyond a single RAS-pathway bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSOS1 pathway program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-5845 adds a second oncology entry point by targeting SOS1, a node in RAS activation biology, instead of only direct KRAS inhibition. That gives Revolution Medicines, Inc. 2 distinct ways to attack RAS-driven tumors and lowers dependence on a single mechanism. This broadens the Ansoff diversification path by expanding the pipeline into a separate biological target class.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emTORC1 signaling program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRMC-5552 targets hyperactive mTORC1 signaling, so Revolution Medicines, Inc. is moving beyond its RAS-only assets into a second cancer-signaling lane. That broadens the pipeline into a new biology class and reduces dependence on one pathway. As of 2026, the program is still early-stage, so the main value is strategic diversification, not near-term sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKRASG12C and NRASG12C\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevolution Medicines, Inc. is diversifying with RMC-6291, which targets ON-state KRASG12C and NRASG12C, not the broader RAS pathway. That creates a tighter market segment defined by mutation and activation state, which can improve selectivity versus wider pathway inhibition. As of 2025, Revolution Medicines, Inc. reported about $1.3 billion in cash, cash equivalents, and marketable securities, supporting this expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets mutant ON-state KRAS and NRAS\u003c\/li\u003e\n\u003cli\u003eCreates a new mutation-defined category\u003c\/li\u003e\n\u003cli\u003eMore selective than broad pathway blockers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKRASG13C and KRASG12D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevolution Medicines’ KRASG13C(ON) and KRASG12D(ON) programs expand diversification by adding mutation-specific shots at distinct RAS variants, creating new product-market pairs in precision oncology. The company is widening beyond a single KRAS path, which can reduce concentration risk and broaden its addressable patient pool.\u003c\/p\u003e\n\u003cp\u003eThat matters in a large market: KRAS mutations are common across solid tumors, and KRASG12D is one of the most frequent oncogenic KRAS alterations in pancreas, colon, and lung cancers. In 2025, Revolution Medicines still had no commercial product revenue, so pipeline breadth is a key value driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eKRASG13C(ON) adds another mutation target.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eKRASG12D(ON) widens the RAS variant basket.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMore targets means less single-asset risk.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevolution Medicines Diversifies with RAS and Non-RAS Pipeline Strength\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevolution Medicines, Inc. uses diversification by adding new RAS and non-RAS targets, so it is not relying on one drug or one pathway. RMC-6291, RMC-5845, and RMC-5552 broaden the pipeline across mutation-defined and signaling-based plays. In 2025, the company reported about $1.3 billion in cash, cash equivalents, and marketable securities, which supports this spread.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eAngle\u003c\/th\u003e\n\u003cth\u003e2025 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-6291\u003c\/td\u003e\n\u003ctd\u003eON-state KRASG12C\/NRASG12C\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMC-5845\u003c\/td\u003e\n\u003ctd\u003eSOS1\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234925453577,"sku":"rvmd-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rvmd-ansoff-matrix.webp?v=1785730622","url":"https:\/\/dcfanalyst.com\/products\/rvmd-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}